These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 23411955)

  • 1. [Impact of preventive administration of antiemetic drugs on risk of acute nausea and vomiting induced by transcatheter arterial chemoembolization in patients with hepatocellular carcinomas - a retrospective study].
    Kabuki M; Higashihara H; Kakuda M; Fujita Y; Masuda J; Kin K; Ueguchi T; Osuga K; Tomiyama N
    Gan To Kagaku Ryoho; 2013 Feb; 40(2):197-201. PubMed ID: 23411955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
    Sakamoto T; Saito Y; Kobayashi M; Yamada T; Takekuma Y; Nakai M; Ogawa K; Iseki K; Sugawara M
    Support Care Cancer; 2020 Jul; 28(7):3251-3257. PubMed ID: 31732854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
    Sohara N; Takagi H; Abe T; Hashimoto Y; Kojima A; Takahashi H; Nagamine T; Mori M
    Support Care Cancer; 1999 Mar; 7(2):84-8. PubMed ID: 10089088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of Azasetron Hydrochloride: a new selective 5-HT3 receptor antagonist--antiemetic profile and plasma concentration in transcatheter arterial chemoembolization using CDDP for unresectable hepatocellular carcinoma].
    Beppu T; Ogawa M; Yamanaka T; Egami H; Ohara C; Masuda Y; Kudo S; Kuramoto M; Doi K; Matsuda T
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1197-202. PubMed ID: 9679583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements.
    Kogut MJ; Chewning RH; Harris WP; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2013 Mar; 24(3):326-31. PubMed ID: 23380736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
    Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
    Wang SY; Zhu WH; Vargulick S; Lin SB; Meng ZQ
    Asian Pac J Cancer Prev; 2013; 14(10):5995-6000. PubMed ID: 24289614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
    Nicolaides C; Giannakakis T; Skarlos D; Athanassiadis A; Fountzilas G; Damigos D; Pavlidis N
    J Exp Clin Cancer Res; 1998 Mar; 17(1):71-5. PubMed ID: 9646236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exploration of indication of prophylactic transcatheter arterial chemoembolization on postoperative recurrence of hepatocellular carcinoma].
    Wang QX; Yan JJ; Zhou FG; Shen J; Yan YQ
    Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):748-51. PubMed ID: 19615209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting survival in advanced T-staged hepatocellular carcinoma patients treated with reduction hepatectomy followed by transcatheter arterial chemoembolization.
    Kobayashi A; Takahashi S; Ishii H; Konishi M; Nakagohri T; Gotohda N; Satake M; Furuse J; Kinoshita T
    Eur J Surg Oncol; 2007 Oct; 33(8):1019-24. PubMed ID: 17399939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography.
    Xia Y; Kudo M; Minami Y; Hatanaka K; Ueshima K; Chung H; Hagiwara S; Inoue T; Ishikawa E; Kitai S; Takahashi S; Tatsumi C; Ueda T; Hayaishi S; Maekawa K
    Oncology; 2008; 75 Suppl 1():99-105. PubMed ID: 19092278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter arterial chemoembolization confers survival benefit in patients with a spontaneously ruptured hepatocellular carcinoma.
    Kim JY; Lee JS; Oh DH; Yim YH; Lee HK
    Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):640-5. PubMed ID: 22395224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Lin CI; Lin ZY; Hsieh MY; Huang CF; Chen SH; Chuang WL
    Kaohsiung J Med Sci; 2011 Dec; 27(12):554-9. PubMed ID: 22208538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of transcatheter arterial chemoembolization in the prevention of postoperative recurrence in 1630 patients with hepatocellular carcinoma].
    Cheng HY; Xu W; Xu AM; Chen D; Yang YF; Jia YC
    Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):626-8. PubMed ID: 16438876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
    Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
    J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.